Search clinical trials for: Glucose Canagliflozin

Total 3280 results

Beijing Anzhen Hospital

Recruiting

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Coronary Artery Disease | Diabete Mellitus

China
University of Turin, Italy

Unknown

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors (GliRACo1)

Diabetes Mellitus, Type 2 | Body Weight Changes | Arterial Hypertension

Italy
Janssen-Cilag International NV

Completed

A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers

Healthy

Germany
Hvidovre University Hospital

Unknown

Glucose Absorption and Gut Hormone Secretion After Gastric Bypass

Overweight

Denmark
Center for Outcomes Research and Clinical Epidemiology...
Italian Society of Diabetology

Not yet recruiting

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation Trial (GOLDEN-AGE)

Diabetes Mellitus, Type 2
Peking Union Medical College Hospital

Unknown

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study of Canagliflozin in Healthy Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Brazil
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study to Determine Blood Levels of JNJ-28431754 (Canagliflozin) in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Dose Proportionality Study of Canagliflozin in Healthy Volunteers

Healthy

Belgium
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion

Type 1 Diabetes

United States
Janssen Research & Development, LLC

Completed

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Diabetes Mellitus, Type 2

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of 28431754 (Canagliflozin) on Gastrointestinal Glucose Absorption and Metabolism in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus (CANVAS-R)

Diabetes Mellitus, Type 2 | Albuminuria

Australia, France, Italy, Poland, Ukraine, United Kingdom, United States, China, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Malaysia, Canada, Netherlands, Korea, Republic of, New Zealand, Brazil, Russian Federation, Puerto... and more
Janssen Research & Development, LLC

Completed

A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Diabetes Mellitus, Type 1

United States, Canada
Yale University

Terminated

Glycemic Index of Commonly Consumed Sweeteners

Healthy

United States
Barmherzige Brüder Linz

Unknown

Cardiometabolic Effects of Rapid Glucose Excursion (ERGE)

Diabetes Mellitus, Experimental

Austria
GlucoMe

Withdrawn

GLUCOME USABILITY STUDY

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1
Janssen Research & Development, LLC

Completed

A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea

Diabetes Mellitus, Type 2

China, Malaysia, Vietnam
The Cleveland Clinic
Janssen Scientific Affairs, LLC

Terminated

CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes

Obesity | Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC
The George Institute for Global Health, Australia

Completed

CANVAS - CANagliflozin cardioVascular Assessment Study (CANVAS)

Cardiovascular Diseases | Diabetes Mellitus, Type 2 | Risk Factors

United States, Australia, Poland, Ukraine, United Kingdom, Belgium, Germany, France, Spain, Argentina, Colombia, Israel, Mexico, India, Canada, Netherlands, Sweden, Malaysia, New Zealand, Estonia, Russian Federation, Hungary, Norway, ... and more
The University of Texas Health Science Center at...
Janssen Scientific Affairs, LLC

Withdrawn

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Cardiovascular Diseases | Type2 Diabetes Mellitus

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers

Healthy

United States
Johnson & Johnson Private Limited

Completed

A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting

Diabetes Mellitus, Type 2

India
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic and Pharmacodynamic Study of Metformin and Canagliflozin in Healthy Adult Volunteers

Healthy
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function

Healthy | Renal Insufficiency

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
AstraZeneca

Completed

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

Healthy

China
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain
McGill University Health Centre/Research Institute...
Heart and Stroke Foundation of Canada

Not yet recruiting

Canagliflozin in Advanced Renal Disease With MRI Endpoints (CARe-MRI)

ESRD, CKD Stage 4, CKD Stage 5
Hospital Universitari Vall d'Hebron Research Institute

Unknown

Canagliflozin in Postprandial Hyperinsulinemic Hypoglycemia (CANA-PHH-RYGB) (CANA-PHH-RYGB)

Postprandial Hypoglycemia

Spain
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin IR Tablets (2 x 1,000 mg) in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

Type 1 Diabetes Mellitus

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Diabetes Mellitus, Type 2

United States, Australia, Germany, Canada, France
Foundation for Atlanta Veterans Education and Research...
Janssen Scientific Affairs, LLC

Active, not recruiting

Canagliflozin-Mealtime Insulin Rescue

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN 8)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, United Kingdom, Canada, Sweden, Ireland, Argentina, Brazil, Lebanon, Malaysia, Mexico, Italy
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Cairo University
Aswan Heart Centre

Completed

Clinical Outcomes of Dapagliflozin in Acute Heart Failure With Reduced Ejection Fraction (CODA-HFrEF)

Acute Heart Failure

Egypt
National Cheng-Kung University Hospital

Completed

SGLT-2 Inhibitor Effects on Cardiac and Hepatic Metabolic Profiles for the Diabetes Patients Combined With Obesity

Fatty Liver Disease

Taiwan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

Healthy

United States
Hiddo Lambers Heerspink
AstraZeneca

Unknown

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria (DIAMOND)

Chronic Kidney Diseases | Proteinuria

Canada, Malaysia, Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Drug Interaction Study of Warfarin and Canagliflozin in Healthy Adult Volunteers

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

France, Poland, United Kingdom, United States, Spain, Colombia, India, Romania, South Africa, Ukraine, Australia, Canada, Greece, Sweden, New Zealand, Switzerland, Hong Kong

Search clinical trials for: Glucose Canagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations